• Join
  • Login
  • Contact

Search abstracts

Poor medication adherence in clinical trials: consequences and solutions

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Presentation
  • By: VRIJENS, Bernard (WestRock Healthcare & University of Liège, Belgium, Healthcare, Vise, Belgium)
  • Co-author(s): Alasdair Breckenridge : Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom
    Jeffrey K Aronson: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom
    Terrence F Blaschke: Dept of Medicine, Stanford University School of Medicine, Stanford, United States
    Dan Hartman : Global Health, Bill and Melinda Gates Foundation, Seattle, United States
    Carl Peck: Dept of Bioengineering and Therapeutic Sciences, University of California, San Francisco, United States
    Bernard Vrijens: Healthcare, WestRock , Vise, Belgium;Biostatistics, University of Liège, Liège, Belgium
  • Abstract:


    The crucial importance of patient adherence to medication was captured by the former US Surgeon General, C. Everett Koop when he said “Drugs don’t work in patients who don’t take them”. Patient adherence, defined as how drugs are taken as prescribed, involves three actions by the patient: initiation of therapy, implementation of the


  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses